Human Immunodeficiency Virus Type 1: Drug Resistance in Treated and Untreated Brazilian Children

Memorias do Instituto Oswaldo Cruz

Volumn 98, Issue 6, 2003, Pages 831-837

  Simonetti, S R R ^a   Schatzmayr, H G ^a   Simonetti, J P ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Brazilian children; Drug resistance; Genotyping; Human immunodeficiency virus type 1 (HIV 1)

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ANTIBIOTIC RESISTANCE; ARTICLE; AUTOMATION; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENOME ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; SYMPTOM; VIRUS GENOME; VIRUS ISOLATION; VIRUS MUTANT; VIRUS STRAIN; WILD TYPE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0345731036     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762003000600021     Document Type: Article

References (40)

1. Bloor S, Hertogs K, Larder B, Pauwels R, Larder BA 1998. Virological basis for HIV-1 resistance to stavudine investigated by analysis of clinical samples [abstract 15]. Antivir Ther 3 (Suppl. 1): 15-16.
2. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillen PME, Noordaa J van der 1990. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28: 495-503.
3. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP, Wainberg MA 2002. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 76: 1753-1761.
4. Condra JH, Holder DJ, Schleif WA 2000a. Genetics correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure. Antivir Ther 4 (Suppl. 1): 44.
5. Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Yang T, Chodakewitz JA, Deutsch PJ, Leavitt RY, Massari FE, Mellors JW, Squires KE, Steigbigel RT, Teppler H, Emini EA 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 70: 8270-8276.
6. Condra JH, Petropoulos CJ, Ziermann R, Schleif WA, Shivaprakash M, Emini EA 2000b. Drug resistance and predicted virologie responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis 182: 758-765.
7. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374: 569-571.
8. Dronda F, Casado JL, Moreno S, Hertogs K, Garcia-Arata I, Antela A, Perez-Elias MJ, Ruiz L, Larder B, the NELSANE Study 2001. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene. AIDS Res Hum Retroviruses 17: 211-215.
9. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P 1999. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. The Lancet 353: 2195-2199.
10. Fitzgibbon JE, Howell RM, Haberzettl CA, Sperber SJ, Gocke DJ, Dubin DT 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 36: 153-157.
11. Furman PA, Fyfe JA, ST Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, Barry DW 1986. Phosphorylation of 3′ azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83: 8333-8337.
12. Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter L, Vella S, Jacobsen DM, Richman DD 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 283: 2417-2426.
13. Huang W, Limoli K, Sartoris MM, Petropoulos C, Whitcomb J 1999. Complex interactions involving multiple amino acid substitutions alter NNRTI susceptibility [abstract 73]. Antivir Ther 4 (Suppl. 1): 50-51.
14. Huang W, Gamarnik A, Wrin T 2000. NNRTI-resistance profiles, replicative capacity and protease processing defects in HIV-1 that contain RT mutations at amino acid 190 [abstract 29]. Antivir Ther 5 (Suppl. 3): 23.
15. Johnson VA, Petropoulos CJ, Woods CR, Hazelwood JD, Parkin NT, Hamilton CD, Fiscus SA 2001. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis 183: 1688-1693.
16. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E, Rode RA 2001. Identification of genotypic changes in human immuno-deficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 75: 7462-7469.
17. Kohl NE, Emini EA, Schleif WA 1998. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 85: 4686-4690.
18. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC 1993. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 167: 526-532.
19. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, Morris D, Hubbell E, Chee M, Gingeras TR 1996. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 2: 753-759.
20. Larder BA, Kellam P, Kemp SD 1991. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5: 137-144.
21. Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G, Tisdale M 2000. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 14: 163-171.
22. Mitsuya H, Yarchoan R, Broder S 1990. Molecular targets for AIDS therapy. Science 249: 1533-1544.
23. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo H-M, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CAB, Leonard JM, Norbeck DW , Kempf DJ 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 2: 760-766.
24. Nájera I, Holguín A, Quiñones-Mateu ME, Munoz-Fernandez MA, Nájera R, López-Galindez C, Domingo E 1995. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 69: 23-31.
25. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13: 2349-2359.
26. Parkin NT, Chappey C, Maranta M, Whitehurst N, Petropoulos C 2001. Genotypic and phenotypic analysis of a large database of patient samples reveals distinct patterns of cross-resistance. Antivir Ther 6: 49.
27. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44: 920-928.
28. Pieniazek D, Rayfield M, Hu DJ, Nkengasong J, Wiktor SZ, Downing R, Biryahwaho B, Mastro T, Tanuri A, Soriano V, Lal R, Dondero T 2000. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naïve individuals worldwide. AIDS 14: 1489-1495.
29. Richman DD, Guatelli JC, Grimes J, Tsiatis A, Gingeras TR 1991. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction. J Infect Dis 164: 1075-1081.
30. Schmit J-C, Cogniaux J, Hermans P, Vaeck CV, Sprecher S, Remoortel BV, Witvrouw M, Balzarini J, Desmyter J, De Clercq E, Vandamme A-M 1996. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis 174: 962-968.
31. Schmit J-C, Van Laethem K, Ruiz L, Hermans P, Sprecher S, Sönnerborg A, Leal M, Harrer T, Clotet B, Arendt V, Lissen E, Witvrouw M, Desmyter J, De Clercq E, Vandamme A-M 1998. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 12: 2005-2015.
32. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PA, Arnold E 1994. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 243: 369-387.
33. Tisdale M, Alnadaf T, Cousens D 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 41: 1094-1098.
34. Tisdale M, Kemp SD, Parry NR, Larder BA 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 90: 5653-5656.
35. Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N, Cameron J 1995. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9: 351-357.
36. Wainberg MA, White AJ 2001. Current insights into reverse transcriptase inhibitor-associated resistance. Antivir Ther 6: 11-19.
37. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, Katzenstein DA, Merigan TC 1998. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 102: 1769-1775.
38. Winters MA, Hughes M, Lustgarten S, Katzehstein DA 2001. Effect of treatment history and reverse transcriptase gene mutations on response of nucleoside reverse transcriptase inhibitor-experienced patients to combination therapy with zidovudine plus didanosine plus lamivudine [abstract 131]. Antivir Ther 6 (Suppl. 1): 96-97.
39. Winters MA, Shafer RW, Jellinger RA, Mmtora G, Gingeras T, Merigan TC 1997. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 41: 757-762.
40. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B 1999. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 131: 813-821.